Get the Stockscreener App
0.44
0.00%
0.00
After Hours:
.46
0.02
+4.55%
Mereo Biopharma Group Plc Adr stock is traded at $0.44, with a volume of 7.37M.
It is up +0.00% in the last 24 hours and up +18.76% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$0.44
Open:
$0.44
24h Volume:
7.37M
Relative Volume:
0.55
Market Cap:
$70.02M
Revenue:
$10.00M
Net Income/Loss:
$-29.47M
P/E Ratio:
-2.20
EPS:
-0.2
Net Cash Flow:
$-21.55M
1W Performance:
-16.52%
1M Performance:
+18.76%
6M Performance:
-74.71%
1Y Performance:
-84.98%
1-Day Range:
$0.425
$0.4949
1-Week Range:
$0.42
$0.5201
52-Week Range:
$0.20
$3.255
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.44 | 70.02M | 10.00M | -29.47M | -21.55M | -0.20 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.90 | 120.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.45 | 78.77B | 14.34B | 4.50B | 3.88B | 41.57 |
|
ARGX
Argen X Se Adr
|
840.50 | 52.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
338.06 | 45.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
340.38 | 38.73B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-25 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
MREO Stock Price, Forecast & Analysis | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plcMREO - Sahm
Mereo BioPharma Group’s (MREO) “Buy” Rating Reiterated at BTIG Research - Defense World
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock? - MSN
A Look At Mereo BioPharma Group (MREO) Valuation After Mixed Setrusumab Phase 3 Results And Cash Runway Update - Sahm
Why Mereo BioPharma (MREO) Is Up 69.9% After Mixed Setrusumab Phase 3 Results And Pipeline Shift - Sahm
MREO: Setrusumab delivers robust BMD and pain improvements in OI, with key regulatory steps ahead - TradingView — Track All Markets
Mereo BioPharma Group (NASDAQ:MREO) Given New $3.00 Price Target at Needham & Company LLC - Defense World
MREO: Late-stage rare disease pipeline advances with strong data, strategic partnerships, and solid cash runway - TradingView — Track All Markets
Mereo BioPharma updates setrusumab program, extends cash runway - Investing.com
Mereo BioPharma updates setrusumab program, extends cash runway By Investing.com - Investing.com India
Mereo BioPharma Provides Corporate Update - Investing News Network
10 Stocks Under $1 That Will Explode - Insider Monkey
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Mereo BioPharma Group Sees Unusually High Options Volume (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Sees Unusually Large Options Volume (NASDAQ:MREO) - MarketBeat
RARE, MREO Tank as Osteogenesis Study Fails to Meet Primary Endpoint - Finviz
Jefferies downgrades Mereo BioPharma stock to Hold after setrusumab trial failure - Investing.com UK
Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain - Sahm
Mereo BioPharma Group’s (MREO) Market Perform Rating Reaffirmed at Lifesci Capital - Defense World
Mereo BioPharma Group (NASDAQ:MREO) Given New $1.00 Price Target at BTIG Research - Defense World
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com UK
United States shares lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com India
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.51% - Investing.com
Mereo BioPharma stock price target cut by BTIG to $1 from $6 - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures By Investing.com - Investing.com South Africa
Baird lowers Mereo BioPharma stock price target to $1 from $8 after trial failures - Investing.com UK
Ultragenyx stock plummets 43% after setrusumab fails in Phase III trial - Investing.com India
Silver Tumbles 8%; Society Pass Shares Spike Higher - Sahm
Dow Falls Over 100 Points; US Pending Home Sales Rise In November - Sahm
Mereo BioPharma stock plummets after failed Phase 3 trials By Investing.com - Investing.com South Africa
Mereo BioPharma stock plummets after failed Phase 3 trials - Investing.com India
Mereo BioPharma, Ultragenyx Pharmaceutical And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mereo’s setrusumab fails primary endpoint in osteogenesis imperfecta trials By Investing.com - Investing.com India
Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab in Osteogenesis Imperfecta - Investing News Network
Ultragenyx-Mereo Bone Drug Trial Disappoints, Stocks Hit 52-Week Lows - Sahm
Mereo BioPharma Group (NASDAQ:MREO) Receives Buy Rating from Needham & Company LLC - Defense World
Mereo BioPharma Group’s (MREO) “Buy” Rating Reaffirmed at BTIG Research - Defense World
BTIG reiterates Buy rating on Mereo BioPharma stock ahead of key trial data - Investing.com UK
683 Capital Management LLC Decreases Stock Holdings in Mereo BioPharma Group plc – Sponsored ADR $MREO - Defense World
Traders Purchase High Volume of Put Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually Large Options Trading (NASDAQ:MREO) - MarketBeat
Investors Buy High Volume of Call Options on Mereo BioPharma Group (NASDAQ:MREO) - Defense World
Mereo BioPharma Group Target of Unusually High Options Trading (NASDAQ:MREO) - MarketBeat
It makes sense and dollars to buy Mereo Biopharma Group Plc ADR (MREO) stock - setenews.com
Baird names Mereo BioPharma stock a Fresh Pick ahead of OI data - Investing.com UK
Mereo BioPharma Group And 2 Undervalued Penny Stocks To Watch - Yahoo Finance
This trade activity should not be overlooked: Mereo Biopharma Group Plc ADR (MREO) - Setenews
Mereo BioPharma Group plc (MREO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Equities Analysts Issue Forecasts for MREO FY2025 Earnings - Defense World
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):